0000000000344857

AUTHOR

Job F M Van Boven

showing 6 related works from this author

Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study

2019

BACKGROUND: The lack of centralised data on severe asthma has resulted in a scarcity of information about the disease and its management. The development of a common data collection tool for the International Severe Asthma Registry (ISAR) will enable standardised data collection, subsequently enabling data interoperability.OBJECTIVES: To create a standardised list of variables for the first international registry for severe asthma via expert consensus.METHODS: A modified Delphi process was used to reach consensus on a minimum set of variables to capture in ISAR: the core variables. The Delphi panel brought together 27 international experts in the field of severe asthma research. The process…

MaleConsensusInternationalityDelphi TechniqueeducationDelphi method03 medical and health sciences0302 clinical medicineDisease registryWorkbookHumansImmunology and AllergyMedicineMedical historyRegistries030212 general & internal medicineCase report formcomputer.programming_languageData collectionbusiness.industryasthmamedicine.diseaseInverse synthetic aperture radar030228 respiratory systembiologicalsREGISTRYFemaleMedical emergencybusinesscomputerDelphiSpecialization
researchProduct

Mapping 123 million neonatal, infant and child deaths between 2000 and 2017

2019

Since 2000, many countries have achieved considerable success in improving child survival, but localized progress remains unclear. To inform efforts towards United Nations Sustainable Development Goal 3.2—to end preventable child deaths by 2030—we need consistently estimated data at the subnational level regarding child mortality rates and trends. Here we quantified, for the period 2000–2017, the subnational variation in mortality rates and number of deaths of neonates, infants and children under 5 years of age within 99 low- and middle-income countries using a geostatistical survival model. We estimated that 32% of children under 5 in these countries lived in districts that had attained ra…

SurvivalRJ101Mortalidad InfantilHBUNDER-5 MORTALITYGlobal HealthPediatrics0302 clinical medicine3123 Gynaecology and paediatricsChild deathInfant MortalityEpidemiologyGlobal healthMiddle income countryNacimiento vivo030212 general & internal medicine10. No inequalityChildPOPULATIONDeveloping worldeducation.field_of_studyPublic healthMultidisciplinaryGeographyMortality ratewa_9001. No povertyRSUCCESSPediatrikA900 Others in Medicine and Dentistry3142 Public health care science environmental and occupational health3. Good healthChild MortalityDeath childrenVACCINATIONHEALTHws_100INTERVENTIONSAFRICAmedicine.medical_specialtyUnited NationsGeneral Science & Technology030231 tropical medicinePopulationDeveloping countryArticleHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]ITC-HYBRID03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterSocial JusticeRecién nacidoNeonatal deathsmedicineSYSTEMATIC ANALYSISOrganizational ObjectivesHumanseducationDeveloping Countriesbusiness.industryPublic healthInfant NewbornInfantCIVIL REGISTRATIONPaediatricsChild survivalNewbornPREVENTIONMortality rateInfant mortalitywa_320ws_200Child mortalitySocioeconomic FactorsITC-ISI-JOURNAL-ARTICLEHuman medicinePaediatrics Public health Developing worldbusinessDemography
researchProduct

Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Devel…

2020

BACKGROUND: Sustainable Development Goal (SDG) 3 aims to "ensure healthy lives and promote well-being for all at all ages". While a substantial effort has been made to quantify progress towards SDG3, less research has focused on tracking spending towards this goal. We used spending estimates to measure progress in financing the priority areas of SDG3, examine the association between outcomes and financing, and identify where resource gains are most needed to achieve the SDG3 indicators for which data are available. METHODS: We estimated domestic health spending, disaggregated by source (government, out-of-pocket, and prepaid private) from 1995 to 2017 for 195 countries and territories. For …

Economic growthFinancing GovernmentPsychological interventionHIV Infectionsburden of disease030204 cardiovascular system & hematologyDISEASEALLOCATION0302 clinical medicineRA0421RA0421 Public health. Hygiene. Preventive MedicineSustainable developmentGlobal healthhealth economicsHealthcare FinancingHIV Infection030212 general & internal medicine10. No inequality11 Medical and Health SciencesDALYHealthy lives1. No povertyPublic Health Global Health Social Medicine and Epidemiology3rd-DASGeneral MedicineSustainable Development3. Good healthtuberculosisIMPOVERISHMENTTERRITORIESFinancingHumanFinancing PersonalResource (biology)Tuberculosi195 COUNTRIESDeveloping Countrie03 medical and health sciencesSDG 3 - Good Health and Well-beingAcquired immunodeficiency syndrome (AIDS)General & Internal MedicineSYSTEMATIC ANALYSISmedicineHumansBurden HIV/AIDS tubercolosis malariaHuman resourcesDeveloping CountriesSustainable developmentGovernmentAcquired Immunodeficiency SyndromeHealth economicsbusiness.industryDISABILITYCATASTROPHEGlobal Burden of Disease Health Financing Collaborator NetworkGLOBAL BURDENmedicine.diseaseMalariaSDG; health sector spending; development assistant for health.Health ExpenditureFolkhälsovetenskap global hälsa socialmedicin och epidemiologi3121 General medicine internal medicine and other clinical medicineNAHealth ExpendituresbusinessEXPENDITURE
researchProduct

Spacers and Valved Holding Chambers—The Risk of Switching to Different Chambers

2020

© 2020 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

corticosteroidSpacerinhalation spacerQ1lung03 medical and health sciences0302 clinical medicineDrug Delivery SystemsdysphoniaRC705InhalersAdministration InhalationImmunology and AllergyMedicineHumansmetered dose inhaler030212 general & internal medicineMetered Dose InhalershumanParticle Sizesnoutbusiness.industryInhaleradultthroat irritationInhalerarticleValved holding chamberrisk assessmentR735Equipment DesignReduced doseValved Holding ChambersMetered-dose inhalerthrushR1030228 respiratory systemDelivery systembusinessvalveBiomedical engineeringInhalation Spacers
researchProduct

Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 20…

2020

Artículo con numerosos autores. Sólo se hace referencia al primero que coincide con el de la UAM y al colectivo

MaleRespiratory diseasesRespiratory Tract DiseasesDiseaseChronic respiratory diseasesGlobal Burden of DiseasePulmonary Disease Chronic Obstructive0302 clinical medicineCost of Illness11. SustainabilityMETABOLIC RISKSEPIDEMIOLOGY030212 general & internal medicineChildCause of deathAged 80 and overCOPDDALYChronic obstructive pulmonary diseaseMortality rateRespiratory disease1. No povertyAge FactorsMiddle AgedDeath causes3. Good healthPREVALENCEHealth risksChild PreschoolCOMPARATIVE RISK-ASSESSMENTFemaledeath and disability worldwideQuality-Adjusted Life YearsTERRITORIESBURDENgrowth in absolute numbersPulmonary and Respiratory MedicineAdultADJUSTED LIFE-YEARSHealth burdensAdolescentMedicina195 COUNTRIESchronic respiratory diseasesArticle1117 Public Health and Health Services03 medical and health sciencesYoung AdultLife ExpectancySex FactorsBurden of Disease Respiratory diseaseSarcoidosis PulmonaryEnvironmental healthmedicineDisability-adjusted life yearHumansCOPDEXPOSURERisk factorMortalityAgedper-capita basisbusiness.industryDISABILITYInfant NewbornInfant1103 Clinical Sciencesasthmamedicine.diseaseAsthmaYears of potential life lost030228 respiratory systemRisk factors13. Climate actionSystematic analysesChronic DiseaseINJURIESHuman medicinePneumoconiosisMorbiditybusinessLung Diseases Interstitial1199 Other Medical and Health Sciences
researchProduct

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

2018

Abstract Background The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. Methods We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. Results At least 1 risk factor for immunocompromis…

0301 basic medicineMalePediatricsEtiologyMultidrug-resistant pathogenMRSAPneumocystis pneumoniaPneumònia adquirida a la comunitatHOSPITALIZED-PATIENTS0302 clinical medicineCommunity-acquired pneumoniaRisk FactorsPrevalenceMedicine030212 general & internal medicinePNEUMOCYSTIS PNEUMONIAArticles and CommentariesAged 80 and overRespiratory tract infectionsAnemia AplasticMiddle Aged3. Good healthCommunity-Acquired InfectionsEuropeInfectious DiseasesImmunocompromise; Microbiology; MRSA; Multidrug-resistant pathogens; PneumoniaEtiologiaHematologic NeoplasmsFemaleBLOOD-STREAM INFECTIONSLung TransplantationMicrobiology (medical)medicine.medical_specialtyAsiaNeutropeniaCommunity-acquired pneumonia030106 microbiologyRESPIRATORY-TRACT INFECTIONSHematologic NeoplasmsSettore MED/10 - Malattie Dell'Apparato RespiratorioTRANSPLANT RECIPIENTSDISEASES-SOCIETYMicrobiology03 medical and health sciencesImmunocompromised HostPneumonia BacterialMANAGEMENTHumanspneumoniaBACTERIAL PNEUMONIAImmunocompromiseAgedAcquired Immunodeficiency Syndromebusiness.industrymicrobiologyBacterial pneumoniaAustraliaPneumoniamedicine.diseaseMultidrug-resistant pathogensPneumoniamultidrug-resistant pathogensMycosesBacteremiaAfricaEtiologyRISK-FACTORSimmunocompromiseAmericasbusinessClinical Infectious Diseases
researchProduct